Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection
The landscape of GI toxicity from targeted cancer therapies is expanding rapidly. Accurate recognition of characteristic pathology patterns and integration with clinical history are crucial for safe and effective management. Enhanced pharmacovigilance, pathology-oncology collaboration, and incorporation of national surveillance data (FAERS, SEER) are essential to advancing precision medicine and patient safety.
Authors
- Muhammad Usama Ashraf (ORCID: https://orcid.org/0000-0001-9827-092X)
- Talha Kamran Khan
- Mahima Gandhi
- M. Nauman Qureshi
- Feroza Fatima
- Mohammad Saud Khan (ORCID: https://orcid.org/0000-0001-5055-3226)
- Muhammad Moseeb Ali Hashim (ORCID: https://orcid.org/0000-0001-5376-6884)
- Hafsa Hameed Thakur
- Muhammad Ahsan
- Sania Muzaffar
- Kamran Zahoor
- Shamama Tu Zahra
- Ammara Naeem
Institutions
- University of Tennessee Health Science Center (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Oncoscience
- Published
- 2025-12-30
- DOI
- https://doi.org/10.18632/oncoscience.643
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00